DOGE shutters lease on FDA lab in St. Louis and 29 other sites
The Department of Government Efficiency says that it has terminated the leases of 30 FDA offices and buildings, including a 52,000 square-foot St. Louis-based lab that operates under the FDA's Office...
View ArticleTeladoc holds out for 2026
Teladoc is in a rebuilding era. Once a stock market darling during the pandemic, the telehealth giant has been forced to reinvent itself. Its forecasted revenue for 2025 is flat ...
View ArticleMisleading promotion lands NJ drugmaker a letter from FDA
Edenbridge Pharmaceuticals received this year's first untitled letter from the FDA's drug promotion office over misleading claims in an advertisement for the company's multiple myeloma drug Hemady. The...
View ArticleChina bans imports of Illumina's DNA sequencers following US tariffs
China will ban the import of DNA sequencers from San Diego-based Illumina, an apparent response to additional US tariffs. Last month, the Chinese government placed Illumina on an "unreliable entities"...
View ArticlePersica shares early data for antibiotic in chronic back pain
Persica Pharmaceuticals said it has promising Phase 1b results that support its approach of using a two-dose antibiotic to treat a subset of patients with chronic back pain. Chronic low back pain in...
View ArticleEli Lilly seeks pitches from US states for slice of $27B manufacturing buildout
Eli Lilly is doing something out of the box to find where it should pour its latest manufacturing commitment. In a company first, the pharma giant is welcoming pitches from US ...
View ArticleBayer cautions pharma sales dip this year despite major upcoming launches
Bayer said Wednesday its pharmaceuticals unit will likely see a decline in sales in 2025, as the company reported another set of lackluster earnings amid its best efforts at a multiyear turnaround. The...
View ArticleJazz to buy Chimerix for $935M to get brain tumor drug five months ahead of...
Jazz Pharmaceuticals will buy North Carolina biotech Chimerix for $935 million in cash, the companies said Wednesday morning. Through the deal, Jazz gets access to a potential first-ever treatment for...
View ArticleBhattacharya hearing updates: Trump NIH nominee faces Senate
Stanford researcher Jay Bhattacharya appears headed for a relatively easy Senate confirmation, following a two-hour hearing where he was pressed on several controversial topics but largely appeared to...
View ArticleFDA puts BioNTech’s malaria vaccine on clinical hold
BioNTech has paused an early-stage study of its experimental malaria vaccine after the FDA handed it a clinical hold, the biotech disclosed Tuesday in a securities filing. The company did not provide a...
View ArticleBristol Myers' MyoKardia unit ends work with Fulcrum; ALX discloses layoffs
Plus, news about Amgen, Tenax Therapeutics and Celon Pharma: Fulcrum Therapeutics loses a partner: Bristol Myers Squibb’s MyoKardia unit told Fulcrum last week that it is terminating a
View ArticleNovo Nordisk slashes Wegovy price for patients without insurance
Novo Nordisk cut the price of its weight loss blockbuster Wegovy by nearly two-thirds for certain patients paying outside of insurance, following a similar move by Eli Lilly. Novo’s new program...
View ArticleTrump administration reverses course on FDA drug quality lab closure
Two days after announcing plans to shut down an FDA lab devoted to ensuring the US drug supply remains safe and potent, the Trump administration has changed plans and will leave the lab open, ...
View ArticleBavarian Nordic CEO says reshoring manufacturing to the US can take years
While reshoring pharma production to the US is not impossible, government officials need to be aware that it could take five to 10 years to complete the process, Bavarian Nordic CEO Paul Chaplin...
View ArticleNovo Nordisk will join lawsuit over end of semaglutide shortage
Novo Nordisk got the green light to join a lawsuit by compounders against the FDA after the agency deemed that the Danish pharma's blockbuster weight loss drug was no longer in shortage. Judge Mark...
View ArticleJudge grants new nationwide block on NIH payment cuts
A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. Judge Angel ...
View ArticleITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera
ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal data...
View ArticleNovo Nordisk looks into starting GLP-1 drug trials for addiction
Novo Nordisk is considering investigating its GLP-1 therapies in the treatment of addictions, mirroring similar comments made by its major incretin rival Eli Lilly. Novo is already studying its GLP-1...
View ArticleNo news is good news? Merck KGaA quiet on potential SpringWorks takeover
Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its potential buyout of SpringWorks Therapeutics. But the German pharma was...
View Article